Bendalina (bendazac lisina) / Angelini Group - LARVOL DELTA

Potential Application of Bendazac L-Lysine for Controlling Myopia Progression, as Demonstrated in Two Experimental Guinea Pig Myopia Models. (PubMed, Invest Ophthalmol Vis Sci) - "BDL significantly suppressed myopia development in experimentally induced myopia in guinea pigs. This study suggests that BDL may be a viable candidate for myopia control."

Journal • Ophthalmology • AKR1B1

Ameliorating effect of the aldose reductase inhibitor 1-Acetyl-5-phenyl-1 H-pyrrol-3-ylacetate on galactose-induced cataract. (PubMed, Sci Rep) - "Our observations suggest that APPA is more effective than bendazaclysine in alleviating high galactose-induced oxidative stress (The malondialdehyde content in the APPA group and bendazaclysine group was significantly reduced to 0.45-fold and 0.58-fold compared to the high galactose-induced group, respectively.) and apoptosis (The apoptosis rate in the APPA group and bendazaclysine group was significantly reduced to 0.28-fold and 0.35-fold compared to the high galactose-induced group, respectively.) in lens epithelial cells by increasing antioxidant enzyme activity, and restoring mitochondrial homeostasis...In the galactose-induced cataract rat model, APPA is effective in alleviating the occurrence of galactose-induced cataract. In conclusion, APPA with multiple synergistic functions may be a potential drug to alleviate the occurrence of diabetic cataract, and it has a wider range of indications than benzydalysine."

Journal • Cataract • Diabetes • Metabolic Disorders • Ophthalmology • AKR1B1

Exploring Synthetic Strategies for 1H-Indazoles and Their N-Oxides: Electrochemical Synthesis of 1H-Indazole N-Oxides and Their Divergent C-H Functionalizations. (PubMed, Angew Chem Int Ed Engl) - "Owing to the rich reactivity of 1H-indazole N-oxides, diverse C-H functionalization reactions were performed. We demonstrated the synthetic utility of 1H-indazole N-oxides by synthesizing the pharmaceutical molecules lificiguat and YD (3); key intermediates for bendazac, benzydamine, norepinephrine/serotonin reuptake inhibitors, SAM-531, and gamendazole analogues; and a precursor for organic light-emitting diodes."

Journal

Engineering a multi-target therapy nanoplatform against tumor growth and metastasis via a novel NSAID-Pt(IV) prodrug. (PubMed, Chem Commun (Camb)) - "The complexity means that a multi-target combination therapy strategy should be selected against tumor growth and metastasis. Here, cisplatin (CDDP) and bendazac (Ben) were designed as a novel NSAID-Pt(IV) nanoplatform, which is an effective weapon for combating tumor growth and metastasis."

Journal • Oncology

Investigation into the Emerging Role of the Basic Amino Acid L-Lysine in Enhancing Solubility and Permeability of BCS Class II and BCS Class IV Drugs. (PubMed, Pharm Res) - "Drugs-lysine salt/complexes were confirmed. Solubility enhancement factors ranged from 68- to 433-fold increases and dissolution rates were also significantly enhanced by up to 6-times, compared with drugs alone. With the exception of rutin-lysine, P for bendazac-lysine and quercetin-lysine enhanced by 2.3- to 4-fold. P for quercetin (Class IV) benefited more than bendazac (Class II) when complexed with lysine. This study warrants the use of L-lysine as a promising excipient for enhanced solubility and permeability of Class II and Class IV, providing that the solubility of the drug is ensured at 'the door step' of absorption sites."

Journal